dc.date.accessioned2022-10-12T18:25:57Z
dc.date.available2022-10-12T18:25:57Z
dc.date.created2022-10-12T18:25:57Z
dc.date.issued2022
dc.identifierhttps://hdl.handle.net/20.500.12866/12368
dc.identifierhttps://doi.org/10.1002/alz.12757
dc.description.abstractLimited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.
dc.languageeng
dc.publisherWiley
dc.relationAlzheimer's and Dementia
dc.relation1552-5279
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectBiomarkers
dc.subjectdementia
dc.subjectLatin America
dc.titleBiomarkers for dementia in Latin American countries: Gaps and opportunities
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución